Ulcerative Colitis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

UC MCID: ULC004 MIFTS: 75	Ulcerative Colitis (UC) Categories: Gastrointestinal diseases, Immune diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Ulcerative Colitis

MalaCards integrated aliases for Ulcerative Colitis:

Name: Ulcerative Colitis ¹¹ ⁴² ⁷⁵ ⁴¹ ¹⁴ ³⁶ ¹⁶ ⁷¹ ³¹ ³³

Left Sided Ulcerative Colitis ⁷¹ ³³

Colitis Gravis ⁴² ³³

Inflammatory Bowel Disease, Ulcerative Colitis Type ⁴²

Chronic Left-Sided Ulcerative Colitis ⁷¹

Ulcerative Mucosal Proctocolitis ³³

Left-Sided Ulcerative Colitis ¹¹

Chronic Ulcerative Enteritis ³³

Uc - [ulcerative Colitis] ³³

Idiopathic Proctocolitis ⁴²

Mucosal Proctocolitis ³³

Colitis, Ulcerative ⁴³

Colitis Ulcerative ⁵³

Left Hemicolitis ³³

Uc ⁴²

Classifications:

MalaCards categories:
Anatomical: Gastrointestinal diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Diseases of the digestive system

Noninfective enteritis and colitis

Ulcerative colitis

Ulcerative colitis, unspecified

ICD11: ³³

Diseases of the digestive system

Inflammatory bowel diseases

Ulcerative colitis

Left sided ulcerative colitis

Other specified ulcerative colitis

Ulcerative colitis, unspecified

External Ids:

Disease Ontology ¹¹ DOID:8577

ICD9CM ³⁴ 556 556.5

MeSH ⁴³ D003093

NCIt ⁴⁹ C2952

SNOMED-CT ⁶⁸ 196988003 441971007

ICD10 ³¹ K51 K51.9

EFO ¹⁶ EFO_0000729

ICD11 ³³ 784669405 784669405/other 784669405/unspecified more

UMLS ⁷¹ C0009324 C0375359 C2919576

Sources

Summaries for Ulcerative Colitis

MedlinePlus Genetics: ⁴² Ulcerative colitis is a chronic disorder that affects the digestive system. This condition is characterized by abnormal inflammation of the inner surface of the rectum and colon, which make up most of the length of the large intestine. The inflammation usually causes open sores (ulcers) to develop in the large intestine. Ulcerative colitis usually appears between ages 15 and 30, although it can develop at any age. The inflammation tends to flare up multiple times throughout life, which causes recurring signs and symptoms.The most common symptoms of ulcerative colitis are abdominal pain and cramping and frequent diarrhea, often with blood, pus, or mucus in the stool. Other signs and symptoms include nausea, loss of appetite, fatigue, and fevers. Chronic bleeding from the inflamed and ulcerated intestinal tissue can cause a shortage of red blood cells (anemia) in some affected individuals. People with this disorder have difficulty absorbing enough fluids and nutrients from their diet and often experience weight loss. Affected children usually grow more slowly than normal. Less commonly, ulcerative colitis causes problems with the skin, joints, eyes, kidneys, or liver, which are most likely due to abnormal inflammation.Toxic megacolon is a rare complication of ulcerative colitis that can be life-threatening. Toxic megacolon involves widening of the colon and an overwhelming bacterial infection (sepsis). Ulcerative colitis also increases the risk of developing colon cancer, especially in people whose entire colon is inflamed and in people who have had ulcerative colitis for 8 or more years.Ulcerative colitis is one common form of inflammatory bowel disease (IBD). Another type of IBD, Crohn disease, also causes chronic inflammation of the intestines. Unlike ulcerative colitis, which affects only the inner surface of the large intestine, Crohn disease can cause inflammation in any part of the digestive system, and the inflammation extends deeper into the intestinal tissue.

MalaCards based summary: Ulcerative Colitis, also known as left sided ulcerative colitis, is related to inflammatory bowel disease 1 and pouchitis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Ulcerative Colitis is IFNG-AS1 (IFNG Antisense RNA 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Magnesium citrate and Ciprofloxacin have been mentioned in the context of this disorder. Affiliated tissues include Bone, colon and bone marrow, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and growth/size/body region

MedlinePlus: ⁴¹ Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Disease Ontology: ¹¹ A colitis that is predominantly confined to the mucosa located in colon and includes characteristic ulcers, or open sores.

Wikipedia: ⁷⁵ Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon... more...

Sources

Related Diseases for Ulcerative Colitis

Diseases related to Ulcerative Colitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1667)

#	Related Disease	Score	Top Affiliating Genes
1	inflammatory bowel disease 1	33.9	TNF TLR2 NOD2 IL23R IL1B IL10
2	pouchitis	32.9	TNF NOD2
3	cholangitis, primary sclerosing	32.8	TNF NOD2 IL4 IL1B IL10 HLA-DRB1
4	pyoderma gangrenosum	32.8	TNF NOD2 IL1B
5	crohn's disease	32.7	TNF TLR2 REG4 NOD2 IL4 IL23R
6	colitis	32.7	TNF TLR2 STAT6 ST6GALNAC1 REG4 NOD2
7	bowel dysfunction	32.6	TNF NOD2 IL1B IL10
8	chemical colitis	32.5	TNF NOD2 IL1B IL10
9	cholangitis	32.5	TNF NOD2 IL2 IL10 HLA-DRB1
10	inflammatory bowel disease	32.4	TNF TLR2 STAT6 ST6GALNAC1 REG4 NOD2
11	pyoderma	32.2	TNF NOD2 IL1B
12	common cold	32.2	TNF IL4 IL2 IL1B IL13 IL10
13	diarrhea	32.1	TNF NOD2 IL2 IL1B IL13 IL10
14	colonic benign neoplasm	32.1	TNF MLH1 IL1B IL10
15	crohn's colitis	32.0	TNF NOD2 IL1B IL10
16	vasculitis	32.0	TNF IL1B IL10 HLA-DRB1
17	irritable bowel syndrome	32.0	TNF TLR2 IL4 IL1B IL10
18	ileitis	32.0	TNF TLR2 NOD2 IL10
19	spondyloarthropathy 1	31.8	TNF NOD2 IL23R IL1B IL10
20	dysentery	31.8	TNF IL1B IL10
21	appendicitis	31.8	TNF IL2 IL1B IL10 IFNG
22	takayasu arteritis	31.8	TNF IL23R IL10 HLA-DRB1
23	herpes zoster	31.7	TLR2 IL2 IL10 IFNG HLA-DRB1
24	enterocolitis	31.7	TNF NOD2 IL10
25	autoimmune disease	31.7	TNF IL4 IL23R IL2 IL1B IL13
26	purpura	31.7	TNF IL4 IL2 IL1B IL10 IFNG
27	spondylitis	31.7	TNF NOD2 IL23R IL1B IL10 IFNG
28	erythema nodosum	31.6	TNF NOD2 IL1B IL13 IL10 IFNG
29	ileus	31.6	TNF IL1B IL10 IFNG
30	proteasome-associated autoinflammatory syndrome 1	31.6	TNF TLR2 IL4 IL1B IL13 IL10
31	gastritis	31.6	TNF IL4 IL1B IL10
32	exanthem	31.6	TNF IL4 IL2 IL1B IL10 IFNG
33	autoimmune hepatitis	31.6	TNF IL10 IFNG HLA-DRB1
34	allergic disease	31.6	TNF IL4 IL2 IL1B IL13 IL10
35	hypereosinophilic syndrome	31.5	IL4 IL2 IL13 IL10 IFNG
36	pericarditis	31.5	TNF IL1B IFNG
37	bronchiectasis	31.5	TNF TLR2 IL1B IFNG
38	celiac disease 1	31.5	TNF TLR2 NOD2 IL4 IL23R IL2
39	peptic ulcer disease	31.5	TNF IL1B IL10
40	primary biliary cholangitis	31.5	TNF IL4 IL2 IL1B IL10 HLA-DRB1
41	myocarditis	31.5	TNF IL4 IL2 IL1B IL10 IFNG
42	amebiasis	31.4	TNF TLR2 IL4 IL1B IL10
43	pneumonia	31.4	TNF TLR2 IL4 IL1B IL13 IL10
44	duodenal ulcer	31.4	TNF IL1B IL10 HLA-DRB1
45	sarcoidosis 1	31.4	TNF NOD2 IL2 IL1B IL13 IL10
46	alopecia	31.4	TNF IL4 IL2 IL1B IFNG HLA-DRB1
47	uveitis	31.4	TNF NOD2 IL4 IL23R IL2 IL1B
48	microscopic colitis	31.4	TNF IL1B IL10
49	acne	31.4	TNF TLR2 IL1B IL10
50	gastroenteritis	31.4	TNF IL4 IL1B IL10 IFNG

Comorbidity relations with Ulcerative Colitis via Phenotypic Disease Network (PDN): (show all 11)

Active Peptic Ulcer Disease	Acute Cystitis
Crohn's Disease	Deficiency Anemia
Esophagitis	Hypothyroidism
Inflammatory Bowel Disease 1	Intestinal Obstruction
Iron Deficiency Anemia	Paralytic Ileus
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Ulcerative Colitis:

Sources

Symptoms & Phenotypes for Ulcerative Colitis

UMLS symptoms related to Ulcerative Colitis:

nausea and vomiting; constipation; abdominal pain; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

GenomeRNAi Phenotypes related to Ulcerative Colitis according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	9.47	IL10 IL1B MLH1 NFKB1 TNF
2	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	9.47	IL10 IL1B IL2 MLH1 NFKB1 NOD2
3	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-3	9.47	MLH1 NFKB1

MGI Mouse Phenotypes related to Ulcerative Colitis:

⁴⁵ (show all 12)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	growth/size/body region	MP:0005378	10.31	ABCB1 HLA-DRB1 IFNG IL10 IL13 IL1B
2	homeostasis/metabolism	MP:0005376	10.3	ABCB1 IFNG IL10 IL13 IL1B IL2
3	endocrine/exocrine gland	MP:0005379	10.22	ABCB1 IFNG IL10 IL13 IL2 IL23R
4	immune system	MP:0005387	10.17	ABCB1 IFNG IL10 IL13 IL1B IL2
5	neoplasm	MP:0002006	10.16	IFNG IL10 IL1B IL2 IL23R MLH1
6	digestive/alimentary	MP:0005381	10.15	ABCB1 IFNG IL10 IL13 IL2 IL23R
7	liver/biliary system	MP:0005370	10.13	ABCB1 IFNG IL10 IL2 IL4 NFKB1
8	no phenotypic analysis	MP:0003012	10.1	ABCB1 IFNG IL10 IL13 IL2 IL23R
9	respiratory system	MP:0005388	9.96	IFNG IL10 IL13 IL2 IL4 MLH1
10	skeleton	MP:0005390	9.85	HLA-DRB1 IFNG IL10 IL13 IL1B IL4
11	hematopoietic system	MP:0005397	9.8	ABCB1 IFNG IL10 IL13 IL1B IL2
12	integument	MP:0010771	9.32	IFNG IL10 IL13 IL1B IL4 MLH1

Sources

Drugs & Therapeutics for Ulcerative Colitis

Drugs for Ulcerative Colitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 353)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Magnesium citrate

Approved

Phase 4

3344-18-1

Ciprofloxacin

Approved, Investigational

Phase 4

85721-33-1, 93107-08-5

2764

Tacrolimus

Approved, Investigational

Phase 4

104987-11-3

6473866 445643

Nicotine

Approved

Phase 4

54-11-5

942 89594

Linaclotide

Approved

Phase 4

851199-59-2

16158208

Hydrocortisone succinate

Approved

Phase 4

2203-97-6

3643

Hydrocortisone acetate

Approved, Vet_approved

Phase 4

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 4

50-23-7

3640 5754

Infliximab

Approved

Phase 4

170277-31-3

Golimumab

Approved

Phase 4

476181-74-5

Mercaptopurine

Approved

Phase 4

50-44-2

667490

Certolizumab pegol

Approved

Phase 4

428863-50-7

Prednisolone phosphate

Approved, Vet_approved

Phase 4

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 4

52-21-1

Prednisolone

Approved, Vet_approved

Phase 4

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 4

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 4

83-43-2

4159 6741

Prednisone

Approved, Vet_approved

Phase 4

53-03-2

5865

Budesonide

Approved

Phase 4

51333-22-3

5281004 40000 63006

Ozanimod

Approved, Investigational

Phase 4

1306760-87-1

25110515 52938427

Mesalazine

Approved

Phase 4

89-57-6

4075

Tofacitinib

Approved, Investigational

Phase 4

477600-75-2

9926791

Azathioprine

Approved

Phase 4

446-86-6

2265

Gabapentin

Approved, Investigational

Phase 4

60142-96-3

3446

Ascorbic acid

Approved, Nutraceutical

Phase 4

50-81-7

54676860 54670067 5785

Prednisolone hemisuccinate

Experimental

Phase 4

2920-86-7

4897

Cathartics

Phase 4

Laxatives

Phase 4

Picosulfate sodium

Phase 4

Calcineurin Inhibitors

Phase 4

Cyclosporins

Phase 4

Vaccines

Phase 4

Heptavalent Pneumococcal Conjugate Vaccine

Phase 4

Chrysarobin

Phase 4

Hydrocortisone 17-butyrate 21-propionate

Phase 4

Immunologic Factors

Phase 4

Hormone Antagonists

Phase 4

polysaccharide-K

Phase 4

Methylprednisolone Acetate

Phase 4

584547

glucocorticoids

Phase 4

Antineoplastic Agents, Hormonal

Phase 4

Neuroprotective Agents

Phase 4

Antiemetics

Phase 4

Bronchodilator Agents

Phase 4

Anti-Asthmatic Agents

Phase 4

Analgesics

Phase 4

Protein Kinase Inhibitors

Phase 4

Immunosuppressive Agents

Phase 4

Tumor Necrosis Factor Inhibitors

Phase 4

Anticonvulsants

Phase 4

Interventional clinical trials:

(show top 50) (show all 1234)

#	Name	Status	NCT ID	Phase	Drugs
1	GLM Dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A Nationwide Multi-centred Randomised Controlled Trial (RCT) Investigating the Use of GLM Dose Adjustment in Ulcerative Colitis (UC).	Unknown status	NCT02687724	Phase 4	Golimumab (GLM)
2	Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing	Unknown status	NCT02998112	Phase 4	fecal microbiota transplantation;Saline
3	Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis: An Open-label,Randomized,Phase IV Clinical Trial	Unknown status	NCT02962245	Phase 4	berberine;regular treatment
4	Exposure-response of Golimumab During Maintenance in Ulcerative Colitis: An Exploratory Pharmacokinetics/Pharmacodynamics Comparison of Different Dose Regimens	Unknown status	NCT04156984	Phase 4	Golimumab Prefilled Syringe
5	Optimization of Golimumab Treatment in Ulcerative Colitis	Unknown status	NCT03669029	Phase 4	Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg;Golimumab treatment optimization.
6	Comparison Between Two Therapeutic Strategies for the Maintenance of Clinical and Endoscopic Remission in Patients With Ulcerative Colitis Treated by Infliximab	Unknown status	NCT03151525	Phase 4	Azathioprine;Infliximab
7	Tolerability and Efficacy of Low-Volume Sodium Picosulfate/Magnesium Citrate Versus 2L Polyethylene Glycol/Ascorbic Acid in Patients With Ulcerative Colitis Undergoing Colonoscopy: A Randomized Controlled Trial	Unknown status	NCT03581149	Phase 4	Sodium Picosulfate/Magnesium Citrate Laxative;2L polyethylene glycol/ascorbic acid
8	Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Serum Drug Levels, Outcomes and Response in Ulcerative Colitis	Unknown status	NCT04006080	Phase 4
9	A Randomized, Double-blind Study Investigating the Efficacy and Safety of Mesalazine With Hydrocortisone Sodium Succinate (100mg QD) Enema for 4-Week Treatment in Patients With Ulcerative Colitis (UC)	Unknown status	NCT03110198	Phase 4	Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
10	Pilot Study to Evaluate the Efficacy of Golimumab for Induction and Maintenance of Clinical and Endoscopic Remission in Patients With Steroid-dependent Ulcerative Colitis	Unknown status	NCT02412085	Phase 4	Golimumab
11	Personalised Medicine: a Break Through Approach for Early Determination of Anti Tumor Necrosis Factor (TNF) Responders and Non Responders Among Patients With Ulcerative Colitis in a Prospective Study With Golimumab (Simponi)	Unknown status	NCT02186886	Phase 4	Golimumab
12	Probiotic for the Restoration of Intestinal Permeability and Reduction of Intestinal Inflammation in Active Ulcerative Colitis: A Double Blind Randomized Placebo Controlled Trial	Unknown status	NCT01479660	Phase 4	Probiotic
13	The Effect of Probiotics on Bowel Disease	Unknown status	NCT01078935	Phase 4
14	A Prospective Multi-centric Belgian Trial to Validate the Use of Golimumab Serum Level Analysis Using the Dried Blood Spot (DBS) Methodology	Unknown status	NCT02910375	Phase 4
15	Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission.	Unknown status	NCT02452151	Phase 4	Infliximab-Biosimilar;Infliximab-Innovator
16	A Randomized, Multicenter Open Label Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis	Completed	NCT00542152	Phase 4	CYCLOSPORINE VS INFLIXIMAB
17	A Phase IV, Multi-center, Open-label Study to Assess Clinical Recurrence Related to Compliance With Treatment With MMX Mesalamine 2.4g/Day Given Once Daily for the Maintenance of Quiescent Ulcerative Colitis (UC)	Completed	NCT00446849	Phase 4	MMX Mesalamine
18	Combination Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis.	Completed	NCT01941589	Phase 4	oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone;corticosteroids only
19	Golimumab: A Phase 4, UK, Open Label, Single Arm Study on Its Utilization and Impact in Ulcerative Colitis	Completed	NCT02092285	Phase 4	Golimumab
20	An Open Label Interventional Phase 4 Study to Evaluate Efficacy, Safety and Mucosal Healing of Early Versus Late Use of Vedolizumab in Ulcerative Colitis: the LOVE-UC Study (LOw Countries VEdolizumab in UC Study)	Completed	NCT02646657	Phase 4	Vedolizumab 300 mg
21	Test Treat Strategy to Prevent Ulcerative Colitis Relapse	Completed	NCT00652145	Phase 4	mesalamine
22	An Open-Label, Multicenter and Open Enrollment Model, Postmarketing, Milk-Only Lactation Study to Assess Concentration of Vedolizumab in Breast Milk of Lactating Women With Active Ulcerative Colitis or Crohn's Disease Who Are Receiving Vedolizumab Therapeutically	Completed	NCT02559713	Phase 4	Vedolizumab
23	A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY	Completed	NCT02148640	Phase 4	Innovator infliximab;Biosimilar infliximab
24	A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)	Completed	NCT03029143	Phase 4	Vedolizumab IV
25	Use of a Novel Diet (UC DIET) Targeting the Microbiota for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis: An Open Label Pilot Study	Completed	NCT02345733	Phase 4	Antibiotic cocktail
26	A Phase 4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/Day MMX Mesalamine/Mesalazine Once Daily in Adult Subjects With Ulcerative Colitis	Completed	NCT01124149	Phase 4	MMX mesalamine/ mesalazine
27	Open Label Safety and Efficacy Trial of Twice Daily Dosing of Asacol vs. Three Times Per Day Dosing for the Induction of Remission in Active Ulcerative Colitis	Completed	NCT00194818	Phase 4	Asacol (mesalamine)
28	Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205)	Completed	NCT00219414	Phase 4
29	An Open Label, Single Group Assignment Design Study to Correlate Soluble ST2 With Clinical, Endoscopic and Histological Activity in Moderate to Severe Ulcerative Colitis Patients Under Golimumab.	Completed	NCT02318667	Phase 4
30	Multicentre Investigation of the Efficacy and Safety of Adacolumn® GMA in Patients With Steroid-Dependent Active Ulcerative Colitis and Insufficient Response or Intolerance to Immunosuppressants and/or Biological Therapies	Completed	NCT01481142	Phase 4
31	A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effect of Mutaflor in Patients With Mild-to-moderate Ulcerative Colitis on 5-ASA Treatment.	Completed	NCT04969679	Phase 4	E. coli Nissle 1917 (Mutaflor®);Placebo
32	Multicenter Open-label Study Evaluating the Safety and Efficacy of Standardized Initial Therapy Using Either Mesalamine or Corticosteroids Then Mesalamine to Treat Children and Adolescents With Newly Diagnosed Ulcerative Colitis.	Completed	NCT01536535	Phase 4	Mesalazine;IV Corticosteroid;Oral Corticosteroids
33	A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)	Completed	NCT01804166	Phase 4	Infliximab;Golimumab
34	Multi Center Ulcerative Colitis Pediatric Pentasa Intervention Trial (MUPPIT). A Randomized, Single-blinded, Controlled, Parallel, Induction Therapy With Once vs. Twice Daily Dosing of Pentasa in Pediatric UC.	Completed	NCT01201122	Phase 4	Mesalamine
35	Histological and Endoscopic Evaluation of Remission Induced by Infliximab in Moderately to Severely Active Ulcerative Colitis Patients	Completed	NCT01408810	Phase 4	Infliximab
36	Active Ulcerative Colitis; Placebo Controlled Treatment Trial With Ciprofloxacin and E. Coli Nissle	Completed	NCT01772615	Phase 4	Ciprofloxacin
37	Preference for a Prefilled Syringe or Smartject™ Device for Delivering SIMPONI (Golimumab) in Patients Suffering From Moderate to Severe Ulcerative Colitis	Completed	NCT02155335	Phase 4	Prefilled Syringe delivery of Golimumab;Smartject Device delivery of Golimumab
38	Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point-of-care-testing in Inflammatory Bowel Disease: a Pragmatic Trial	Completed	NCT04775732	Phase 4
39	Treatment of Iron Deficiency Anaemia in Adults and Adolescents With Inflammatory Bowel Disease Using Ferrous Sulphate: Tolerance and Effects on Haemoglobin, Mood, Quality of Life and Fatigue	Completed	NCT01991314	Phase 4	Ferrous sulphate
40	The Influence of 5-Aminosalicylates on Thiopurine Metabolite Levels	Completed	NCT00167882	Phase 4	5-aminosalicylate (Pentasa, Ferring)
41	Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels	Completed	NCT03124121	Phase 4	Golimumab
42	Single-dose Linaclotide for Capsule Endoscopy Preparation	Completed	NCT02465385	Phase 4	Linaclotide
43	Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease: A Prospective, Randomized, Double-Blind, Controlled Trial	Completed	NCT01346826	Phase 4	Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
44	Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease	Completed	NCT01341808	Phase 4
45	A Multi-centre Double Blind Randomised Placebo-controlled Study of the Use of Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis	Completed	NCT01418131	Phase 4	Rectal tacrolimus;Placebo
46	Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease	Completed	NCT01908283	Phase 4
47	An Open-label Randomized Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating adaLimumab: The CONTROL Trial	Recruiting	NCT04183608	Phase 4	Adalimumab
48	Combination Therapy With Fecal Microbiota Transplantation and Vedolizumab for Induction of Ulcerative Colitis	Recruiting	NCT04231110	Phase 4
49	VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target	Recruiting	NCT04259138	Phase 4
50	EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis : A Double Blinded Randomized Clinical Trial	Recruiting	NCT03679546	Phase 4	Infliximab;Vedolizumab Injection

Search NIH Clinical Center for Ulcerative Colitis

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Azathioprine

balsalazide

Balsalazide disodium

Hydrocortisone

hydrocortisone acetate

HYDROCORTISONE ACETATE PWDR

HYDROCORTISONE ACETONIDE

Hydrocortisone butyrate

hydrocortisone cypionate

hydrocortisone probutate

HYDROCORTISONE PWDR

Hydrocortisone sodium phosphate

Hydrocortisone sodium succinate

hydrocortisone valerate

HYDROCORTISONE,NONSTERILE PWDR

mesalamine

nicotine polacrilex

olsalazine

Olsalazine sodium

Psyllium

PSYLLIUM HYDROCOLLOID

Sulfasalazine

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Ulcerative Colitis cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Ulcerative Colitis:

	MultiStem, bone marrow-derived cells for inflammatory bowel diseases
	Regenerative ColoTherapy, stem cells for inflammatory bowel diseases

Embryonic/Adult Cultured Cells Related to Ulcerative Colitis:

	Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 21175285
	Adipose-derived mesenchymal stem cells (family)
	Peripheral blood-derived hematopoietic stem cells (family)

Cochrane evidence based reviews: colitis, ulcerative

Sources

Genetic Tests for Ulcerative Colitis

Sources

Anatomical Context for Ulcerative Colitis

Organs/tissues related to Ulcerative Colitis:

FMA: Colon

MalaCards : Colon, Bone Marrow, Liver, Skin, Kidney, Bone, T Cells

Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Ulcerative Colitis:

#	Tissue Anatomical CompartmentCell	Relevance
1	Bone Bone Marrow Bone Marrow Stromal Cells	Potential therapeutic candidate

Sources

Publications for Ulcerative Colitis

Articles related to Ulcerative Colitis:

(show top 50) (show all 30316)

#	Title	Authors	PMID	Year
1	Pilot trial of iBDecide: Evaluating an online tool to facilitate shared decision making for adolescents and young adults with ulcerative colitis. ⁶² ⁴¹	Matula KA...Lipstein EA	36161973	2022
2	Improving Food-Related Quality of Life in Inflammatory Bowel Disease through a Novel Web Resource: A Feasibility Randomised Controlled Trial. ⁴¹	Cox SR...Whelan K	36296976	2022
3	Efficacy of the Panax Notoginseng Ejiao Suppository in the Treatment of Patients with Ulcerative Proctitis and Its Effect on Inflammatory Response and Immune Function. ⁴¹	Liu Y...Lu Q	36188425	2022
4	STAT4 gene influences genetic predisposition to ulcerative colitis but not Crohn's disease in the Spanish population: a replication study. ⁵³ ⁶²	Diaz-Gallo LM...Martin J	20153791	2010
5	TNFalpha is a key mediator of the pronociceptive effects of mucosal supernatant from human ulcerative colitis on colonic DRG neurons. ⁵³ ⁶²	Ibeakanma C...Vanner S	20427396	2010
6	Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis. ⁵³ ⁶²	Pasternak BA...Denson LA	19924809	2010
7	Evidence for STAT4 as a common autoimmune gene: rs7574865 is associated with colonic Crohn's disease and early disease onset. ⁵³ ⁶²	Glas J...Brand S	20454450	2010
8	High gene expression of MDR1 (ABCB1) is associated with medical treatment response and long-term remission in patients with ulcerative colitis. ⁵³ ⁶²	Yamamoto-Furusho JK...Uribe M	19714749	2010
9	Involvement of the IL-22/REG Ialpha axis in ulcerative colitis. ⁵³ ⁶²	Sekikawa A...Fujimori T	20065946	2010
10	Delayed resolution of acute inflammation in ulcerative colitis is associated with elevated cytokine release downstream of TLR4. ⁵³ ⁶²	Rahman FZ...Segal AW	20360984	2010
11	Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. ⁵³ ⁶²	Li Y...van der Woude CJ	19926618	2010
12	MICB0106 gene polymorphism is associated with ulcerative colitis in central China. ⁵³ ⁶²	Li Y...Zhang X	19662431	2010
13	Activation of epithelial STAT3 regulates intestinal homeostasis. ⁵³ ⁶²	Neufert C...Becker C	20160497	2010
14	Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. ⁵³ ⁶²	Eastaff-Leung N...Barry S	19936899	2010
15	A new natural angelica polysaccharide based colon-specific drug delivery system. ⁵³ ⁶²	Zhou S...Mei Q	19408300	2009
16	Decreased sigmoidal ABCB1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity. ⁵³ ⁶²	Ufer M...Cascorbi I	19958093	2009
17	Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis. ⁵³ ⁶²	Masoodi I...Singh K	20136960	2009
18	The relationship between the expression of the glucocorticoid receptor in biopsied colonic mucosa and the glucocorticoid responsiveness of ulcerative colitis patients. ⁵³ ⁶²	Fujishima S...Yamakawa M	19646928	2009
19	Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease. ⁵³ ⁶²	Sakuraba A...Hibi T	19632232	2009
20	Decreased Toll-like receptor-5 (TLR-5) expression in the mucosa of ulcerative colitis patients. ⁵³ ⁶²	Stanislawowski M...Kmiec Z	20083854	2009
21	Down-regulation of protein and mRNA expression of IL-8 and ICAM-1 in colon tissue of ulcerative colitis patients by partition-herb moxibustion. ⁵³ ⁶²	Zhou EH...Zhou S	19083096	2009
22	[IL-6 and TNF-α gene expression in the rectal mucosal of patients with chronic idiopathic ulcerative colitis and controls]. ⁵³ ⁶²	Fonseca-Camarillo GC...Yamamoto-Furusho JK	20423763	2009
23	Frequency of single nucleotide polymorphisms in NOD1 gene of ulcerative colitis patients: a case-control study in the Indian population. ⁵³ ⁶²	Verma R...Paul J	19723304	2009
24	DNA-bound lactoferrin is the major target for antineutrophil perinuclear cytoplasmic antibodies in ulcerative colitis. ⁵³ ⁶²	Teegen B...Komorowski L	19758145	2009
25	Genetics of ulcerative colitis: the come-back of interleukin 10. ⁵³ ⁶²	Louis E...Georges M	19671546	2009
26	HE3286: a novel synthetic steroid as an oral treatment for autoimmune disease. ⁵³ ⁶²	Ahlem C...Nicoletti F	19758229	2009
27	Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. ⁵³ ⁶²	Afif W...Sandborn WJ	19408340	2009
28	Reduction of interleukin-6, interleukin-8, and anti-phosphatidylserine-prothrombin complex antibody by granulocyte and monocyte adsorption apheresis in a patient with pyoderma gangrenosum and ulcerative colitis. ⁵³ ⁶²	Kawakami T...Soma Y	19727102	2009
29	DNA-driven nutritional therapy of inflammatory bowel disease. ⁵³ ⁶²	Lee G...Buchman AL	19647622	2009
30	[The cytokines in inflammatory bowel disease]. ⁵³ ⁶²	Polinska B...Kemona H	19724079	2009
31	[Association of cytotoxic T lymphocyte antigen-4 promoter C-658T polymorphism with ulcerative colitis in Chinese]. ⁵³ ⁶²	Luo Y...Jiang T	20017310	2009
32	Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. ⁵³ ⁶²	Gisbert JP...Mate J	19291780	2009
33	Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease. ⁵³ ⁶²	Song WB...Ma L	19701972	2009
34	Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. ⁵³ ⁶²	Brand S	19592695	2009
35	In situ evidence of involvement of Schwann cells in ulcerative colitis: autocrine and paracrine signaling by A disintegrin and metalloprotease-17-mediated tumor necrosis factor alpha production. ⁵³ ⁶²	Mosnier JF...Laboisse CL	19376560	2009
36	The effect of a new symbiotic formulation on plasma levels and peripheral blood mononuclear cell expression of some pro-inflammatory cytokines in patients with ulcerative colitis: a pilot study. ⁵³ ⁶²	Federico A...Loguercio C	19694343	2009
37	Genetic polymorphisms of interleukin 8 and risk of ulcerative colitis in the Chinese population. ⁵³ ⁶²	Li K...Mao D	19348790	2009
38	Luminal cathepsin g and protease-activated receptor 4: a duet involved in alterations of the colonic epithelial barrier in ulcerative colitis. ⁵³ ⁶²	Dabek M...Bueno L	19528350	2009
39	Dysregulation of human beta-defensin-2 protein in inflammatory bowel disease. ⁵³ ⁶²	Aldhous MC...Satsangi J	19617917	2009
40	Epistasis between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease. ⁵³ ⁶²	Torok HP...Brand S	19455129	2009
41	Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency. ⁵³ ⁶²	Podolsky DK...Cario E	19303021	2009
42	Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. ⁵³ ⁶²	Seow CH...Silverberg MS	19491856	2009
43	Ghrelin ameliorates colonic inflammation. Role of nitric oxide and sensory nerves. ⁵³ ⁶²	Konturek PC...Konturek SJ	19617644	2009
44	Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC). ⁵³ ⁶²	Tahara T...Arisawa T	19184329	2009
45	The combination of polymorphisms within MCP-1 and IL-1beta associated with ulcerative colitis. ⁵³ ⁶²	Li KS...Mao DW	19392835	2009
46	PPARgamma agonists as a new class of effective treatment for ulcerative colitis. ⁵³ ⁶²	Desreumaux P...Dubuquoy L	18798571	2009
47	Cytotoxic T lymphocyte antigen-4 promoter -658CT gene polymorphism is associated with ulcerative colitis in Chinese patients. ⁵³ ⁶²	Luo Y...Zhao Y	19089435	2009
48	GlcNAc6ST-1-mediated decoration of MAdCAM-1 protein with L-selectin ligand carbohydrates directs disease activity of ulcerative colitis. ⁵³ ⁶²	Kobayashi M...Nakayama J	19067429	2009
49	Epithelial tight junctions in intestinal inflammation. ⁵³ ⁶²	Schulzke JD...Fromm M	19538319	2009
50	[TNF alfa polymorphism and course of ulcerative colitis]. ⁵³ ⁶²	Jalocha L...Fiedorowicz E	19606693	2009

Sources

Genes for Ulcerative Colitis

Genes/enhancers related to Ulcerative Colitis (0 elite genes):

(show top 50) (show all 64)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	IFNG-AS1	IFNG Antisense RNA 1	RNA Gene	154.78	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	27492330
2	FOXD2-AS1	FOXD2 Adjacent Opposite Strand RNA 1	RNA Gene	150	Experimental evidence: Regulation ³⁷	26937624
3	H19	H19 Imprinted Maternally Expressed Transcript	RNA Gene	150	Experimental evidence: Expression ³⁷	27661667
4	NOD2	Nucleotide Binding Oligomerization Domain Containing 2	Protein Coding	46.03	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	15052696 12019209 15095125 (more) 17538984 18787464 11425413 17944996 15046221 18438406 18213697 17661913 16361305 16485124 11875755 19253375 16944184 14570728 19305026 19079235 15778542 19455129 16441470 14627676 15638227 17978873 12631666
5	TNF	Tumor Necrosis Factor	Protein Coding	36.08	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	17496730 17567930 8031350 (more) 16856078 19376560 19606693 17652038 9203942 15325795 10321759 12353856 8403503 8683036 11575456 17317344 16733861 9587492 8495600 18346318 12405248 10344681 18277086 14731353 9663825 16110831 7869186 16863613 17990358 1624158 2051274 9468102 11964959 17355842 12184470 9928378 9605921 7821111 1345871 19136378 18598993 18497880 18494836 16822808 11208454 10719056 10491009 10219845 20210765 20485705 20427396 19897959 1517530 19294580 19408340 19258190 17456377 17507924 17956013 16548766 17897045 17967723 17170025 17343083 17255827 16480927 15934825 15102694 10792371 7967129 16927560 14661993 12854551 12385442 11127933 9860399 8926619 7489942 15303463 12020963 8620791 7886987 19491875 18756966 18598998 8194690 18452198 18028805 18575316 17852866 17565649 17300864 17207256 19538319 17412781 17178846 16804395 16038423 15103488 14731126
6	IL10	Interleukin 10	Protein Coding	33.62	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	19758974 15685091 18442197 (more) 18277086 18569989 7729636 8563892 10774465 16298681 17629054 7774055 9843783 19184348 17392581 16118714 19210299 19012039 17343086 16566641 10719056 10551422 18318596 17070109 15918195 11196710 18942752 18624936 11478505 9168497 19694343 12974765 10792371 16733857 12539555 9632923 19671546 8794795 18836448 9665472 11271474 11173905 11531945 14731126
7	IL23R	Interleukin 23 Receptor	Protein Coding	33.14	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	17068223 19175939 20192940
8	IFNG	Interferon Gamma	Protein Coding	31.06	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	15628695 9860336 11069315 (more) 8757634 9922506 8100205 18277086 8563892 8683036 12876555 14517348 15654782 17031175 7821111 9060820 11531945 12525873 14731126 15685091 19538319 19897959 8563891 10219845 10719056 18318596 8580276 1499439 17170025 17343083 15102694 19632232 19294580 8436398 8109803 8926619 10645662 11057923 16520930 7810270 7869186
9	IL13	Interleukin 13	Protein Coding	29.85	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	16048556 18277086 12876555 (more) 16298681 16760750 19538319 9771406 17475330 15146247 16083712 19079225 17545772 15472520 15930983 19079233
10	IL4	Interleukin 4	Protein Coding	29.56	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	11149012 11057923 10425578 (more) 16298681 9060820 11531945 16048556 17343083 11294568 9860336 17420939 8757634 12525873 8794795 9771406 9836081
11	ST6GALNAC1	ST6 N-Acetylgalactosaminide Alpha-2,6-Sialyltransferase 1	Protein Coding	29.24	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Functions (show sections)
12	TLR2	Toll Like Receptor 2	Protein Coding	28.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	18942754 17595233 18040078 (more) 17565650 19303021 19072354
13	ABCB1	ATP Binding Cassette Subfamily B Member 1	Protein Coding	28.11	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	17242936 19005421 16706074 (more) 19770098 15102868 15778512 14724799 16374256 17206689 15505619 17255827 19115152 16416180 19958093 19786771 17665184 19714749 16462040 19288029 12512026 16434865 15920164 17365992
14	NFKB1	Nuclear Factor Kappa B Subunit 1	Protein Coding	28.03	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	14613970 16804398 17852842
15	MLH1	MutL Homolog 1	Protein Coding	27.58	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	9230812 15626886 18507080 (more) 19371218 17276933 12011151 18223333 15069531
16	HLA-DRB1	Major Histocompatibility Complex, Class II, DR Beta 1	Protein Coding	26.53	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	16426241
17	REG4	Regenerating Family Member 4	Protein Coding	26.21	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Functions (show sections)	17260007 12819006
18	IL2	Interleukin 2	Protein Coding	25.1	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
19	IL1B	Interleukin 1 Beta	Protein Coding	24.66	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8403503 1644332 8549067 (more) 1624158 8904520 7869186 8583293 16033908 18346318 8082495 8563892 9468102 11686217 11173905 12468823 14731126 8033515 1639222 15603339 12539555 7886987 9860399 1442335 15955209 10219845 9649212 19936899 15198989 9219791 19724079 1740278 19694343 17611673 10792371 10380697 12567438 9414973 7502804 7543040 1427374 8307455 12525873 11926949 9246063 12572877 17031175 19392835
20	STAT6	Signal Transducer And Activator Of Transcription 6	Protein Coding	24.46	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	17074026 12605697 15888279
21	ATG16L1	Autophagy Related 16 Like 1	Protein Coding	24.34	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
22	MPO	Myeloperoxidase	Protein Coding	24.25	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8406154 8432453 9791051 (more) 8406152 7986968 9093012 11138332 15819166 9773480 9155585 20136960 11370121 9658754 9110485 10102970 8296665 19408300 1329495 7787158 9617859
23	HSPA4	Heat Shock Protein Family A (Hsp70) Member 4	Protein Coding	24.14	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Summaries (show sections)	1638774 9150951 8869289
24	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	24.13	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8801200 9161479 1312411 (more) 1329495 8977339 19348790 9617859 18442197 7489942 8004812 12353856 8406154 8563892 8794794 9468102 10535602 12525873 9361176 17449633 10453373 1359743 12697917 11127933 9260803 9252512 8926619 8178948 18956592 12868194 12682548 9831837 18942752 11095335 10520846 10086655 19727102 19694343 17854143 9753275 9072008 7502804 7967129 17941093 17394078 15603339 15955209 19083096 16682428 10433925 11495082 12871178 17031175
25	IRGM	Immunity Related GTPase M	Protein Coding	23.96	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
26	FOXP3	Forkhead Box P3	Protein Coding	23.95	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
27	IL10RA	Interleukin 10 Receptor Subunit Alpha	Protein Coding	23.59	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
28	TLR4	Toll Like Receptor 4	Protein Coding	23.53	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15207785 17538633 16085746 (more) 18942754 17595233 18040078 17927684 15194649 18680223 19072354 20360984
29	CRP	C-Reactive Protein	Protein Coding	23.5	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18566104 8452705 17436102 (more) 11498080 11943955 17132919 19903425 1624158 9831403 1720888 9507565 8680901 17374324 11232695 9058126 1722373 20454571 16474109 12822883 17924558 17587359 15472532 2093781 17916108 15628695 12934959 18499234 8307455 12419286 14648981 16327837 16437691
30	CTNNB1	Catenin Beta 1	Protein Coding	23.34	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
31	MSH2	MutS Homolog 2	Protein Coding	23.31	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	18223333
32	IL6	Interleukin 6	Protein Coding	23.28	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11740227 1773961 8403503 (more) 9922506 20423763 9507565 8307455 8112497 7683293 8904520 2266787 9753275 8563892 9468102 11204808 12871178 17031175 17629054 7973432 15603339 15303463 12020963 11914023 9058126 1359743 12792220 12214155 11127933 19936899 12682548 1370661 18942752 18383395 19727102 15932502 10792371 8583293 7890234 8101242 1639222 18825772 17507924 16733857 10219845 7769191 19758229 7936613 9928378 12385446 16012934
33	IL5	Interleukin 5	Protein Coding	23.15	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
34	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	22.89	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
35	BTNL2	Butyrophilin Like 2	Protein Coding	22.87	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
36	IL10RB	Interleukin 10 Receptor Subunit Beta	Protein Coding	22.85	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
37	MUC2	Mucin 2, Oligomeric Mucus/Gel-Forming	Protein Coding	22.83	Novoseek inferred ⁵³ GeneCards inferred via : Publications Summaries (show sections)	10026326 8702401 9722984 (more) 10419600 8813081 15097436 9591701 8707087 1327701
38	REL	REL Proto-Oncogene, NF-KB Subunit	Protein Coding	22.8	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
39	MYO9B	Myosin IXB	Protein Coding	22.69	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
40	IL17A	Interleukin 17A	Protein Coding	22.28	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18926293 19936899
41	IRF5	Interferon Regulatory Factor 5	Protein Coding	22.27	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
41	IRF5::GH07J128932	TSS distance: +0.5kb Elite enhancer with elite association with IRF5			Curated enhancer-disease association ²³ ¹³	24196873
42	UCN	Urocortin	Protein Coding	22.18	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Proteins (show sections)	12519893 15974983
43	INAVA	Innate Immunity Activator	Protein Coding	22.18	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
44	TPMT	Thiopurine S-Methyltransferase	Protein Coding	22.17	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11927101 11007234 16795981 (more) 19217567 17697207 14505139 16431304 17026564
45	SMAD7	SMAD Family Member 7	Protein Coding	22.1	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
46	GATA3	GATA Binding Protein 3	Protein Coding	21.88	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
47	TGFB1	Transforming Growth Factor Beta 1	Protein Coding	21.82	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
48	SMAD3	SMAD Family Member 3	Protein Coding	21.79	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
49	SMAD4	SMAD Family Member 4	Protein Coding	21.79	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
50	DUOX2	Dual Oxidase 2	Protein Coding	21.77	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)

Sources

Variations for Ulcerative Colitis

Sources

Expression for Ulcerative Colitis

Genes differentially expressed in tissues of Ulcerative Colitis patients vs. healthy controls: ³⁵ (show all 12)

#	Gene	Description	Tissue	Up/Dn	Fold Change (log2)	P value
1	CLDN8	claudin 8	Colon	-	4.72	0.000
2	LCN2	lipocalin 2	Colon	+	4.60	0.000
3	REG3A	regenerating family member 3 alpha	Colon	+	4.41	0.001
4	SLC26A2	solute carrier family 26 member 2	Colon	-	4.19	0.000
5	PCK1	phosphoenolpyruvate carboxykinase 1	Colon	-	4.13	0.000
6	CXCL8	C-X-C motif chemokine ligand 8	Colon	+	3.86	0.003
7	CXCL2	C-X-C motif chemokine ligand 2	Colon	+	3.85	0.000
8	REG1A	regenerating family member 1 alpha	Colon	+	3.68	0.005
9	RGS3	regulator of G protein signaling 3	Colon	+	3.58	0.000
10	CXCL1	C-X-C motif chemokine ligand 1	Colon	+	3.55	0.000
11	OLFM4	olfactomedin 4	Colon	+	3.25	0.014
12	DEFA6	defensin alpha 6	Colon	+	3.22	0.003

Search GEO for disease gene expression data for Ulcerative Colitis.

Sources

Pathways for Ulcerative Colitis

Pathways related to Ulcerative Colitis according to GeneCards Suite gene sharing:

(show top 50) (show all 78)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	14.03	TNF TLR2 STAT6 NOD2 NFKB1 IL4
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.87	IL10 IL13 IL1B IL2 IL23R IL4
3	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.68	IFNG IL10 IL13 IL1B IL2 IL23R
4	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.6	TNF STAT6 NFKB1 IL4 IL2 IL1B
5	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.53	TNF TLR2 STAT6 NFKB1 IL4 IL2
6	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.47	TNF TLR2 STAT6 NFKB1 IL4 IL23R
7	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.41	HLA-DRB1 IFNG IL10 IL13 IL1B IL2
8	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.37	TNF NFKB1 IL4 IL23R IL2 IL1B
9	IL-9 Signaling Pathways ⁶⁵ Show member pathways Adipocytokines and Insulin Signaling ⁶⁵ Common Cytokine Receptor Gamma-Chain Family Signaling Pathways ⁶⁵ Development Thrombopoietin-regulated cell processes ²² IL-15 Signaling Pathways ⁶⁵ IL-2 Signaling Pathways ⁶⁵ IL-21 Signaling Pathways ⁶⁵ IL-4 Pathway ⁶⁴ IL-4 Signaling Pathways ⁶⁵ IL-7 Signaling Pathways ⁶⁵ IL-9 Pathway ⁶⁴ Immune response IL-9 signaling pathway ²² Interleukin-9 signaling ⁶⁶	12.93	TNF STAT6 NFKB1 IL4 IL2 HLA-DRB1
10	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.88	TNF TLR2 NFKB1 IL2 IL1B
11	Nuclear receptors meta-pathway ⁷⁴ Show member pathways NRF2 pathway ⁷⁴	12.8	TNF IL2 IL1B IFNG ABCB1
12	NF-KappaB Family Pathway ⁶⁴ Show member pathways NF-KappaB (p50-p65) Pathway ⁶⁴	12.76	TNF TLR2 NFKB1 IL2 IL1B
13	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.74	TNF STAT6 IL4 IL23R IL2 IL1B
14	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.71	IFNG IL10 IL1B IL2 IL23R NFKB1
15	NF-kappaB Signaling ³	12.66	IFNG IL10 IL1B IL2 IL4 NFKB1
16	Toll-Like receptor Signaling Pathways ⁶⁵ Show member pathways Inflammasome Activation Pathways ⁶⁵ Nanomaterial-induced inflammasome activation ⁷⁴ NOD-like Receptor Signaling Pathways ⁶⁵ TLR4 signaling and tolerance ⁷⁴ Toll-Like Receptors Pathway ⁶⁴	12.6	IL1B NFKB1 NOD2 TLR2 TNF
17	Interleukin-1 family signaling ⁶⁶ Show member pathways Interleukin-1 signaling ⁶⁶ Interleukin-18 signaling ⁶⁶ Interleukin-38 signaling ⁶⁶	12.56	NOD2 NFKB1 IL4 IL1B IL13
18	Bacterial infections in CF airways ²² Show member pathways Altered glycosylation of MUC1 in tumor microenvironment ⁷⁴ IL-1 beta-dependent CFTR expression ²² IL1-mediated signaling events ⁶¹ Immune response Bacterial infections in normal airways ²² Immune response TLR signaling pathways ²² NTHi-Induced Signaling ⁶⁴ Signal transduction through IL1R ⁷⁴	12.52	TNF TLR2 NFKB1 IL4 IL1B IFNG
19	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.47	NFKB1 IL2 IL1B IL13
20	Toll Comparative Pathway ⁶⁴ Show member pathways IL-1 Pathway ⁶⁴ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶⁴ TLR-TRIF Pathway ⁶⁴	12.35	TNF NFKB1 IL1B IFNG
21	Colorectal Cancer Metastasis ⁶⁴	12.29	TNF TLR2 NFKB1 MLH1 IFNG
22	Sudden infant death syndrome (SIDS) susceptibility pathways ⁷⁴	12.27	TNF NFKB1 IL1B IL13 IL10
23	Immune response CD16 signaling in NK cells ²² Show member pathways Immune response Role of DAP12 receptors in NK cells ²²	12.26	TNF IL4 IL2 IFNG
24	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.24	TNF NFKB1 IL4 IL23R IL2 IL10
25	Neuroinflammation and glutamatergic signaling ⁷⁴	12.18	TNF STAT6 NFKB1 IL4 IL1B IL13
26	MAPK Pathway ⁷⁰ Show member pathways Toll-like Receptor Pathway ⁷⁰	12.14	IL13 IL1B IL2 NFKB1 TLR2
27	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	12.11	TNF IL4 IL2 IL10 IFNG
28	Spinal cord injury ⁷⁴	12.11	TNF IL4 IL2 IL1B IFNG
29	IL12-mediated signaling events ⁶¹ Show member pathways Immune response IL-12-induced IFN-gamma production ²²	12.11	STAT6 NFKB1 IL4 IL2 IL1B IFNG
30	IL2 signaling events mediated by STAT5 ⁶¹ Show member pathways IL2 signaling events mediated by PI3K ⁶¹ IL2-mediated signaling events ⁶¹ Interleukin-2 signaling ⁶⁶	12.1	NFKB1 IL4 IL2 IFNG
31	Interleukin-4 and Interleukin-13 signaling ⁶⁶	12.1	TNF STAT6 IL4 IL23R IL1B IL13
32	IL27-mediated signaling events ⁶¹ Show member pathways IL12 signaling pathway ⁶⁷ Th1 Differentiation ⁶⁵	12.02	TNF TLR2 IL23R IL2 IL1B IL10
33	Th17 Differentiation ⁶⁵ Show member pathways IL-21 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.98	TLR2 IL4 IL23R IL1B IFNG
34	Activation of NF-KappaB by PKR ⁶⁴ Show member pathways Canonical NF-kB pathway ⁷⁴ Cellular Transformation by HTLV1 ⁶⁴ Inhibition of PKR ⁶⁶ STING pathway in Kawasaki-like disease and COVID-19 ⁷⁴	11.9	TNF NFKB1 IL1B IFNG
35	Glucocorticoid receptor regulatory network ⁶¹	11.9	NFKB1 IL4 IL2 IL13 IFNG
36	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.89	TNF IL4 IL2 IL10 IFNG-AS1 IFNG
37	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.87	IFNG IL10 IL1B IL2 TNF
38	AP-1 transcription factor network ⁶¹	11.83	IL4 IL2 IL10 IFNG
39	Calcineurin-regulated NFAT-dependent transcription in lymphocytes ⁶¹ Show member pathways Calcium signaling in the CD4+ TCR pathway ⁶¹	11.81	IFNG IL2 IL4 TNF
40	Burn wound healing ⁷⁴	11.8	TNF NFKB1 IL1B
41	Acute viral myocarditis ⁷⁴	11.8	IL2 IL10 IFNG
42	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.8	TNF NFKB1 IL2 IL1B IFNG
43	Lung fibrosis ⁷⁴	11.79	TNF IL4 IL1B IL13
44	Th17 cell differentiation pathway ⁷⁴	11.79	IFNG IL1B IL2 IL23R IL4 NFKB1
45	IL 10 signaling pathway ⁶⁷	11.78	TNF NFKB1 IL1B IL10
46	Innate Lymphoid Cells Differentiation ⁶⁵	11.76	TNF IL4 IL23R IL2 IL1B IL13
47	Regulation of Telomerase ⁶¹	11.75	NFKB1 IL2 IFNG
48	miRNAs involvement in the immune response in sepsis ⁷⁴	11.71	TNF NFKB1 IL10
49	IL4-mediated signaling events ⁶¹	11.69	STAT6 IL4 IL10
50	THC Differentiation Pathway ⁶⁴	11.68	HLA-DRB1 IFNG IL10 IL2 IL4 NFKB1

Sources

GO Terms for Ulcerative Colitis

Biological processes related to Ulcerative Colitis according to GeneCards Suite gene sharing:

(show top 50) (show all 58)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription by RNA polymerase II	GO:0045944	10.63	TNF TLR2 STAT6 NOD2 NFKB1 IL4
2	signal transduction	GO:0007165	10.6	HLA-DRB1 IFNG IL10 IL13 IL1B IL4
3	positive regulation of gene expression	GO:0010628	10.5	TNF TLR2 IL4 IL1B IL13 IFNG
4	inflammatory response	GO:0006954	10.45	IL13 IL1B IL23R NFKB1 TLR2 TNF
5	cellular response to lipopolysaccharide	GO:0071222	10.28	TNF NOD2 NFKB1 IL1B IL10
6	defense response to Gram-positive bacterium	GO:0050830	10.24	TNF TLR2 NOD2 IL1B
7	positive regulation of type II interferon production	GO:0032729	10.23	IL1B IL2 IL23R TNF
8	negative regulation of inflammatory response	GO:0050728	10.21	IL10 IL13 IL2 IL4 NFKB1
9	positive regulation of NIK/NF-kappaB signaling	GO:1901224	10.2	TNF TLR2 NOD2 IL1B
10	regulation of insulin secretion	GO:0050796	10.19	TNF IL1B IFNG
11	positive regulation of B cell proliferation	GO:0030890	10.19	IL13 IL2 IL4
12	MAPK cascade	GO:0000165	10.19	TNF NOD2 NFKB1 IL1B
13	negative regulation of type II interferon production	GO:0032689	10.19	NOD2 IL10 HLA-DRB1
14	positive regulation of interleukin-8 production	GO:0032757	10.19	TNF TLR2 NOD2 IL1B
15	positive regulation of nitric oxide biosynthetic process	GO:0045429	10.18	TNF IL1B IFNG
16	lipopolysaccharide-mediated signaling pathway	GO:0031663	10.17	TNF TLR2 IL1B
17	extrinsic apoptotic signaling pathway in absence of ligand	GO:0097192	10.17	IL1B IL2 IL4
18	negative regulation of endothelial cell apoptotic process	GO:2000352	10.16	IL4 IL13 IL10
19	positive regulation of cytokine production	GO:0001819	10.16	TNF IL1B IL10 IFNG
20	JNK cascade	GO:0007254	10.15	IL1B NFKB1 NOD2 TNF
21	positive regulation of immunoglobulin production	GO:0002639	10.13	IL2 IL13 IL10
22	positive regulation of phagocytosis	GO:0050766	10.13	TNF NOD2 IL1B IFNG
23	immune response	GO:0006955	10.13	TNF TLR2 IL4 IL2 IL1B IL13
24	positive regulation of interleukin-17 production	GO:0032740	10.12	IL2 IL23R NOD2
25	positive regulation of osteoclast differentiation	GO:0045672	10.12	TNF IL23R IFNG
26	positive regulation of T cell proliferation	GO:0042102	10.12	IL4 IL23R IL2 IL1B
27	positive regulation of inflammatory response	GO:0050729	10.1	TNF TLR2 IL2 IL1B IFNG
28	negative regulation of interleukin-12 production	GO:0032695	10.09	IL10 NFKB1 NOD2
29	positive regulation of nitric-oxide synthase biosynthetic process	GO:0051770	10.08	IFNG NOD2 TLR2
30	positive regulation of interleukin-6 production	GO:0032755	10.07	IFNG IL1B NOD2 TLR2 TNF
31	positive regulation of membrane protein ectodomain proteolysis	GO:0051044	10.06	IFNG IL1B TNF
32	positive regulation of interleukin-12 production	GO:0032735	10.06	IFNG IL23R NOD2 TLR2
33	positive regulation of cytokine production involved in inflammatory response	GO:1900017	10.05	TNF NOD2 H19
34	positive regulation of heterotypic cell-cell adhesion	GO:0034116	10.04	TNF IL1B IL10
35	positive regulation of chemokine production	GO:0032722	10.04	TNF TLR2 IL1B IFNG
36	astrocyte activation	GO:0048143	10.03	TNF IL1B IFNG
37	positive regulation of interleukin-10 production	GO:0032733	10.03	TLR2 NOD2 IL4 IL13
38	neuroinflammatory response	GO:0150076	10.02	IL4 IFNG
39	toll-like receptor 2 signaling pathway	GO:0034134	10.02	TLR2 NOD2
40	positive regulation of humoral immune response mediated by circulating immunoglobulin	GO:0002925	10.01	TNF NOD2
41	negative regulation of cytokine production involved in immune response	GO:0002719	10.01	IL10 TNF
42	positive regulation of mononuclear cell migration	GO:0071677	10.01	IL4 TNF
43	positive regulation of MHC class II biosynthetic process	GO:0045348	10.01	IL4 IL10 IFNG
44	positive regulation of fever generation	GO:0031622	10	TNF IL1B
45	regulation of isotype switching	GO:0045191	9.99	IL4 IL10
46	negative regulation of interleukin-18 production	GO:0032701	9.99	NOD2 IL10
47	sequestering of triglyceride	GO:0030730	9.98	TNF IL1B
48	positive regulation of isotype switching to IgE isotypes	GO:0048295	9.97	IL4 STAT6
49	positive regulation of nitrogen compound metabolic process	GO:0051173	9.97	IFNG TNF
50	positive regulation of plasma cell differentiation	GO:1900100	9.96	IL10 IL2